SUBJECTIVE AND OBJECTIVE ASSESSMENT OF ENALAPRIL IN PRIMARY RAYNAUDS-PHENOMENON

1 The efficacy and acceptability of enalapril were assessed in a double-blind, randomised, placebo controlled cross-over study in 21 patients with primary Raynaud's phenomenon. 2 Skin temperature was assessed by thermocouples in response to a 15-degrees-C cold water challenge as an index of digital blood flow. 3 Following enalapril there were no significant changes in the number and severity of Raynaud's attacks, and no subjective benefit from treatment as measured by visual analogue scales, 5 point rating scales, and skin temperature response to cold challenge when compared with placebo. 4 Enalapril in a dose of 20 mg daily is ineffective in the management of primary Raynaud's phenomenon.